Repligen Earnings: Stock Spark Ahead?

Repligen Corporations first quarter earnings, set to be released this Tuesday, have investors on edge. Last quarter, the biopharma manufacturing company exceeded revenue estimates with $197.9 million, an 18.1% increase from the previous year. However, it fell short on full-year earnings per share guidance. Analysts anticipate a 13.3% year-over-year revenue growth this quarter, up from 10.4% last year. With peers like West Pharmaceutical Services and Medpace showing strength, Repligens stock has remained stagnant. The sector has seen a 6% average increase over the past month, while Repligens shares have stayed flat. Analysts average price target stands at $179.78, significantly higher than the current $168.84. All eyes will be on Repligens performance to potentially ignite its stock. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/c374c51e82a55c00